Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 11
Submit an article Journal homepage
190
Views
4
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0–1) diffuse large B-cell lymphoma

Enrico DerenziniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, ItalyCorrespondence[email protected]
,
Vittorio StefoniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Cinzia PellegriniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Maria Paola FinaInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Alessandro BroccoliInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Filippo VenturiniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Letizia GandolfiInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Stefano A. PileriInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
,
Maurizio MartelliDepartment of Biotechnology and Haematology, University La Sapienza, Rome, Italy
,
Maria Concetta PettiDepartment of Haematology, Regina Elena Institute-IFO, Rome, Italy
,
Alessio PerrottiDepartment of Haematology, S. Eugenio Hospital, University “Tor Vergata”, Rome, Italy
,
Amalia De RenzoDivision of Haematology, Federico II University, Naples, Italy
,
Francesco ZajaDepartment of Haematology, University of Udine, Udine, Italy
,
Michele BaccaraniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
&
Pier Luigi ZinzaniInstitute of Haematology and Medical Oncology “L. & A. Seràgnoli”, University of Bologna, Bologna, Italy
 show all
Pages 1824-1829 | Received 31 May 2009, Accepted 28 Jul 2009, Published online: 09 Oct 2009

References

  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;339:987–994.
  • Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19:545–552.
  • Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21–26.
  • Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage non-Hodgkin's lymphomas: update of the southwest oncology group (SWOG) randomized trial. Blood 2001;98:742a.
  • Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–3038.
  • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInt) Group. Lancet Oncol 2006;7:379–391.
  • Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849.
  • Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102:596–602.
  • Cheson BD, Horning SJ, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
  • Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
  • Tilly H, Lepage E, Coiffer B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 2003;102:4284–4289.
  • Verdonck LF, Notenboom A, De Jong DD, et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP 21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch–Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007;109:2759–2766.
  • Cunningham D ,Smith P ,Mouncey P ,et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27(Suppl):15s; abstr 8506.
  • Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInt) study. Lancet Oncol 2008;9:435–444.
  • Zinzani PL, Stefoni V, Tani M, et al. MACOP-B Regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leuk Lymphoma 2001;42:989–995.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.